T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.94B |
| 2 |
Broadcom
AVGO
|
+$2.74B |
| 3 |
Microsoft
MSFT
|
+$2.33B |
| 4 |
Advanced Micro Devices
AMD
|
+$1.47B |
| 5 |
GE Aerospace
GE
|
+$1.27B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.42B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$2.44B |
| 3 |
Apple
AAPL
|
+$2.42B |
| 4 |
FISV
Fiserv Inc
FISV
|
+$2.3B |
| 5 |
Eli Lilly
LLY
|
+$1.78B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.73% |
| 2 | Financials | 12.11% |
| 3 | Healthcare | 10.97% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Communication Services | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
ASP Isotopes
ASPI
$549M
| $196K | ﹤0.01% |
26,597
+3,476
| +15% | +$23.3K |
|
2702
LivePerson
LPSN
$35.2M
| $196K | ﹤0.01% |
12,937
-236
| -2% | -$2.79K |
|
2703
Taysha Gene Therapies
TSHA
$1.93B
| $196K | ﹤0.01% |
84,603
+10,578
| +14% | +$23K |
|
2704
Cadiz
CDZI
$296M
| $195K | ﹤0.01% |
65,199
+5,563
| +9% | +$16K |
|
|
FSP
2705
Franklin Street Properties
FSP
$46.6M
| $195K | ﹤0.01% |
118,426
+4,787
| +4% | +$7.98K |
|
2706
Surrozen
SRZN
$281M
| $195K | ﹤0.01% |
21,715
| – | – |
|
2707
Cytek Biosciences
CTKB
$634M
| $194K | ﹤0.01% |
56,821
+3,484
| +7% | +$11.6K |
|
2708
Park-Ohio Holdings
PKOH
$722M
| $193K | ﹤0.01% |
10,774
+578
| +6% | +$10.9K |
|
2709
Superior Group of Companies
SGC
$209M
| $193K | ﹤0.01% |
18,710
+1,020
| +6% | +$10.4K |
|
|
UPB
2710
Upstream Bio Inc
UPB
$381M
| $192K | ﹤0.01% |
+17,448
| New | +$161K |
|
2711
VTEX
VTEX
$637M
| $191K | ﹤0.01% |
+28,917
| New | +$170K |
|
|
STRS
2712
DELISTED
STRATUS PPTYS INC
STRS
| $190K | ﹤0.01% |
10,045
-16
| -0.2% | -$293 |
|
2713
Alto Ingredients
ALTO
$326M
| $189K | ﹤0.01% |
164,000
-4,300
| -3% | -$4.12K |
|
2714
Capricor Therapeutics
CAPR
$253M
| $189K | ﹤0.01% |
19,018
+3,490
| +22% | +$36.9K |
|
2715
Costamare
CMRE
$1.74B
| $188K | ﹤0.01% |
20,596
+1,497
| +8% | +$13.3K |
|
2716
Blue Owl Capital
OBDC
$5.9B
| $188K | ﹤0.01% |
+13,100
| New | +$186K |
|
2717
Aldeyra Therapeutics
ALDX
$90.5M
| $187K | ﹤0.01% |
48,683
+13,600
| +39% | +$35.2K |
|
2718
eHealth
EHTH
$39.7M
| $187K | ﹤0.01% |
42,936
+14,036
| +49% | +$70.4K |
|
2719
Paysafe
PSFE
$420M
| $187K | ﹤0.01% |
14,777
+502
| +4% | +$6.87K |
|
2720
iHeartMedia
IHRT
$478M
| $186K | ﹤0.01% |
105,406
+11,046
| +12% | +$14.7K |
|
2721
Petco
WOOF
$820M
| $186K | ﹤0.01% |
65,624
+4,082
| +7% | +$12.7K |
|
2722
Carter Bankshares
CARE
$757M
| $184K | ﹤0.01% |
+10,556
| New | +$167K |
|
|
NESR
2723
National Energy Services Reunited Corp
NESR
$3.62B
| $184K | ﹤0.01% |
+30,543
| New | +$189K |
|
2724
Ardmore Shipping
ASC
$707M
| $183K | ﹤0.01% |
18,964
+1,003
| +6% | +$9.66K |
|
2725
Eton Pharmaceutcials
ETON
$1.13B
| $183K | ﹤0.01% |
+12,840
| New | +$203K |
|
Similar funds
T. Rowe Price Associates's Q2 2025 Portfolio in Review
As of Q2 2025, T. Rowe Price Associates held 3,193 positions worth $883B, up 8.8% from $812B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2025 filing shows 153 new, 2,010 increased, 803 reduced and 136 closed positions. Its largest new stake was Ralliant Corp: 4,667,638 shares worth $226M. The largest sale was Amazon, an estimated $3.42B.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 30% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q2 2025 buy was Ralliant Corp: 4,667,638 shares worth $226M.
- T. Rowe Price Associates added most to NVIDIA in Q2 2025, an estimated $3.94B increase.
- T. Rowe Price Associates's biggest Q2 2025 reduction was Amazon, cutting an estimated $3.42B.
- T. Rowe Price Associates fully exited US Steel in Q2 2025, selling an estimated $146M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $883B portfolio in Q2 2025.
- T. Rowe Price Associates opened 153 new positions and closed 136 in Q2 2025.
- T. Rowe Price Associates's portfolio value rose 8.8% quarter-over-quarter to $883B.
Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.